Atypical antipsychotics in the treatment of bipolar disorder

Bibliography

• GOODWIN FK, JAMISON KR: Manic-depressive illness. Oxford University Press, London, UK (1990).
   Google Scholar
• MURRAY CJL, LOPEZ AD: 1The global burden of disease: summary Harvard School of public health monograph, Cambridge, MA, USA (1996).
   Google Scholar
• PRIEN RF, CAFFEY EM Jr, KLETT CJ: Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch. Gen. Psychiatry (1972) 26(2):146–153.
   Google Scholar
• ••This large study was one of the firstof its kind to systematically investigate treatments for mania in a large, multi-centre design.
   Google Scholar
• JOHNSON G, GERSHON S, BURDOCK El, FLOYD A, HEKIMIAN L: Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. Br. J. Psychiatry (1971) 119(550):267–276.
   PubMed Web of Science ®Google Scholar
• STRAKOWSKI SM, DELBELLO MP, ADLER CM: Comparative efficacy and tolerability of drug treatments for bipolar disorder. CNS Drugs (2002) 15(9):701–708.
   Web of Science ®Google Scholar
• MCELROY SL, KECK PE JR., STRAKOWSKI SM: Mania, psychosis and antipsychotics. I Chi]. Psychiatry (1996) 57\(Suppl. 3):14–26.
   Google Scholar
• AHLFORS UG, BAASTRUP PC, DENCKER SJ etal.: Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatr. Scam/. (1981) 64(3):226–237.
   Google Scholar
• KECK PE Jr, MCELROY SL, STRAKOWSKI SM: Anticonvulsants and antipsychotics in the treatment of bipolar disorder. j Chi]. Psychiatry (1998) 59\(Suppl. 6):74–81.
   Google Scholar
• STRAKOWSKI SM, MCELROY SL, KECK PE Jr: Efficacy of valproate in bipolar illness: comparisons and contrasts with lithium. In: Pharmacotherapy for mood, anxiety and cognitive disorders. Montgomery S, Halbreich U (Eds), American Psychiatric Press Inc., Washington, DC, USA (2000):143–158.
   Google Scholar
• TOHEN M, SANGER TM, TOLLEFSON GD et al: Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am. j Psychiatry (1999) 156(5):702–709.
   PubMed Web of Science ®Google Scholar
• TOHEN M, JACOBS TG, GRUNDY SL et al: Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch. Gen. Psychiatry (2000) 57(9):841–849.
   PubMed Web of Science ®Google Scholar
• SANGER TM, TOHEN M, VIETA E etal.: Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. j Affect. Disord. (2003) 73(1–2):155–161.
   Google Scholar
• TOHEN M, BAKER RW, ALTSHULER LL et al: Olanzapine versus divalproex in the treatment of acute mania. Am. J. Psychiatry (2002) 159 (6):1011–1017.
   PubMed Web of Science ®Google Scholar
• ••There have been relatively few largecomparisons of current mania treatments, particularly with antipsychotic medications. This study provides one such study.
   Google Scholar
• ZAJECKA JM, WEISLER R, SACHS G etal.: A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. j Clin. Psychiatry (2002) 63(12):1148–1155.
   Google Scholar
• TOHEN M, CHENGAPPA KN, SUPPES T et al.: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch. Gen. Psychiatry (2002) 59(1):62–69.
   PubMed Web of Science ®Google Scholar
• TOLLEFSON GD, SANGER TM, BEASLEY CM, TRAN PV: A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol. Psychiatry (1998) 43(10:803–810.
   PubMedGoogle Scholar
• SHELTON RC, TOLLEFSON GD, TOHEN M et al: A novel augmentation strategy for treating resistant major depression. Am. I Psychiatry (2001) 158(1):131–134.
   PubMed Web of Science ®Google Scholar
• TOHEN M, VIETA E, KETTER TA et al: Olanzapine in the treatment of bipolar depression. Int. j Neuorpsychopharmacol. (2002) 5\(Suppl. 0:5109
   Google Scholar
• TOHEN M, MARNEROS A, BOWDEN C et al: Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomised double-blind controlled 12-month clinical trial. 41st Annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 8–12 (2002).
   Google Scholar
• NASRALLAH H: A review of the effect of atypical antipsychotics on weight. Psychorieuroendocrinology (2003) 28:83–96.
   PubMed Web of Science ®Google Scholar
• ALLISON DB, MENTORE JL, HEO M et al.: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. j Psychiatry (1999) 156:1686–1696.
   PubMed Web of Science ®Google Scholar
• NEMEROFF CB: Dosing the antipsychotic medication olanzapine. I Chi]. Psychiatry (1997) 58\(Suppl. 10):45–49.
   Google Scholar
• BEASLEY CM: Safety of olanzapine. Chi]. Psychiatry Monograph (1997) 15:19–21.
   Google Scholar
• WEIDEN P, AQUILA R, STANDARD J: Atypical antipsychotic drugs and long-term outcome in schizophrenia. j Chi]. Psychiatry (1996) 57\(Suppl. 10:53–60.
   Google Scholar
• WIRSHING DA, SPELLBERG BJ, ERHART SM, MARDER SR, WIRSHING WC: Novel antipsychotics and new-onset diabetes. Biol. Psychiatry (1998) 44:778–783.
   PubMed Web of Science ®Google Scholar
• KORO CE, FEDDER DO, EITALIEN GJet al.: An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidaemia in schizophrenic patients. Arch. Gen. Psychiatry (2002) 59:1021–1026.
   Google Scholar
• GIANFRANCESCO FD, GROGG AL, MAHMOUD RA, WANG R, NASRALLAH HA: Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type-2 diabetes: findings from a large health plan database. j Chi]. Psychiatry (2002) 63:920–930.
   PubMed Web of Science ®Google Scholar
• TOHEN M, ZARATE CA Jr, CENTORRINO F, HEGARTY JI, FROESCHL M, ZARATE SB: Risperidone in the treatment of mania. j Chi]. Psychiatry (1996) 57(6):249–253.
   PubMed Web of Science ®Google Scholar
• VIETA E, HERRAIZ M, PARRAMON G, GOIKOLEA JM, FERNANDEZ A, BENABARRE A: Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. I Affect. Disorder (2002) 72(1):15–19.
   PubMed Web of Science ®Google Scholar
• MCINTYRE R, YOUNG LT, HASEY G, PATELIS-SIOTIS I, JONES BD: Risperidone treatment of bipolar disorder. Carr. J. Psychiatry (1997) 42(1):88–90.
   PubMed Web of Science ®Google Scholar
• LICTH RW, BYSTED M, CHRISTENSEN H: Fixed-dosed risperidone in mania: an open experimental trial. Int. OM. Psychopharmacol (2001) 16(2):103–110.
   PubMed Web of Science ®Google Scholar
• SACHS GS, GROSSMAN F, GHAEMI SN, OKAMOTO A, BOWDEN CL: Combination of a mood stabiliser with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am. j Psychiatry (2002) 159(7):1146–1154.
   PubMed Web of Science ®Google Scholar
• ••Although publication was somewhatdelayed, this study was the first to examine the common practice of combining mood stabilisers and antipsychotic medications for the treatment of acute mania. Although the practice was widespread, until this study, it had not been examined in a controlled design.
   Google Scholar
• HIRSCHFELD R, KECK PE, KARCHER K, KRAMER M, GROSSMAN F: Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. 41stAnnual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 8–12, 2002.
   Google Scholar
• MYERS JE, THASE ME: Risperidone: review of its therapeutic utility in depression. Psychopharmacol Bull. (2001) 35(4):109–129.
   PubMedGoogle Scholar
• SHELTON RC, ADDINGTON S, AUGENSTEIN E, BALL W: Risperidone and paroxetine in bipolar disorder. Annual Meeting of the American Psychiatric Association, New Orleans, Louisiana, USA May 5–10 (2001).
   Google Scholar
• HALBREICH U, KINON BJ, GILMORE JA, KAHN LS: Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychorreuroendocnnology (2003) 28:53–67.
   PubMed Web of Science ®Google Scholar
• JONES HM, TRAVIS MJ, MULLIGAN R et al.: In vivo 5-HT2A receptor blockade by quetiapine an R91150 single photon emission tomography study. Psychopharmacology (Berl) (2001) 157:60–66.
   PubMed Web of Science ®Google Scholar
• DEV V, RANIWALLA J: Quetiapine: a review of its safety in the management of schizophrenia. Drug Safety (2000) 23:295–307.
   PubMed Web of Science ®Google Scholar
• KAPUR S, ZIPURSKY R, JONES C, SHAMMI CS, REMINGTON G, SEEMAN P: A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch. Gen. Psychiatry (2000) 57:553–559.
   PubMed Web of Science ®Google Scholar
• ••An important study to better understandthe mechanism of action of quetiapine and perhaps other mood stabilisers. It re-emphasises the importance of dopamine D2 activity in the antipsychotic effects of these drugs and identifies a potential new mechanism (i.e., transient receptor occupancy) to explain some of the benefits of these compounds.
   Google Scholar
• ADITYANJEE, SCHULZ SC: Clinical use of quetiapine in disease states other than schizophrenia. j Clin. Psychiatry (2002) 63\(Suppl. 13):32–38.
   Google Scholar
• FINDLING RL: Use of quetiapine in children and adolescents. I OM. Psychiatry (2002) 63\(Suppl. 13):27–31.
   Google Scholar
• DELBELLO MP, SCHWIERS ML, ROSENBERG HL, STRAKOWSKI SM: A double-blind, randomised, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. Am. Acad. Child. Adolesc. Psychiatry (2002) 41:1216–1223.
   PubMed Web of Science ®Google Scholar
• ••To our knowledge, this is the only double-blind, randomised, placebo-controlled study of antipsychotic medication in children with bipolar disorder and one of only a very small number of double-blind, randomised, placebo-controlled studies in bipolar children more generally.
   Google Scholar
• SACHS G, MULLEN J, DEVINE N, SWEITZER DE: Quetiapine versus placebo as an adjunct to mood stabiliser for the treatment of acute bipolar mania. Presented at the 31 European Stanley Foundation Conference 017 Bipolar Disorder, September 12–14, 2002.
   Google Scholar
• NEMEROFF CB, KINKEAD B, GOLDSTEIN J: Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. I Chia. Psychiatry (2002) 63\(Suppl. 13):5–11.
   Google Scholar
• KECK PE Jr, MCELROY SL, ARNOLD LM: Ziprasidone: a new atypical antipsychotic. Exp.Opin. Pharmacother. (2001) 2: 1033–1042.
   PubMedGoogle Scholar
• KECK PE Jr, REEVES KR, HARRIGAN EP et al.: Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled trials. OM. Psychopharmacol (2001) 21: 27–35.
   Web of Science ®Google Scholar
• KECK PE Jr, VERSIANI M, POTKIN S et al: Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo- controlled, double-blind, randomised trial. Am. I Psychiatry (2003) (In Press).
   Google Scholar
• KECK PE Jr, BUFFENSTEIN A, FERGUSON J et al.: Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (1998) 140:173–184.
   PubMed Web of Science ®Google Scholar
• DANIEL DG, ZIMBROFF DL, POTKIN SG et al: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo controlled trial. Neuropsychopharmacology (1999) 20: 491–505.
   PubMed Web of Science ®Google Scholar
• REILLY JG, AYIS AS, FERRIER IN, JONES SJ, THOMAS SH: QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet (2000) 355:1048–1052.
   PubMed Web of Science ®Google Scholar
• KECK PE Jr, MARCUS R, TOURKODIMITRIS S, ALI M, SAHA A, INGENITO G: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. I Psychiatry (2003) (In press).
   Google Scholar
• MULLER-OERLINGHAUSEN B, RETZOW A, HENN FA etal.: Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomised, double-blind, placebo-controlled multicenter study. OM. Psychopharmacol. (2000) 20:195–203.
   Google Scholar
• YATHAM LN, GROSSMAN F, AUGUSTYNS I, VIETA E, RAVINDRAN A: Mood stabilisers plus risperidone or placebo in the treatment of acute mania: International, double-blind, randomised controlled trial. Br I Psychiatry (2003) 182:141–147.
   PubMed Web of Science ®Google Scholar
• VIETA E, KHANNA S, VAN KAMMEN D et al: Risperidone monotherapy in acute bipolar mania. 41st Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 8–12 (2002).
   Google Scholar
• MEEHAN K, ZHANG F, DAVID S et al.:A double-blind, randomised comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. OM. Psychopharmacol. (2001) 21:389–397.
   Web of Science ®Google Scholar
• LINDENMAYER JP, CZOBOR P, VOLAKAKA J et al.: Changes in glucose and cholesterol levels in patients with 759 Expert Op/n. Pharmacother. (2003) 4(5) schizophrenia treated with typical or atypical antipsychotics. Am. I Psychiatry (2003) 160:290–296.
   Google Scholar
• NEWCOMER JW, HAUPT DW, FUCETOLA R et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry (2002) 59:337–345.
   PubMed Web of Science ®Google Scholar